Long-Acting Muscarinic Antagonist (LAMA) Inhalersĭual Therapy (LAMA/LABA) Combination Inhalers RightBreathe Short-acting muscarinic antagonist - Inhaler Prescribing Information (with images) Short-Acting Muscarinic Antagonist (SAMA) Inhalers British guideline on the management of asthma NICE (2019): Patient decision aid - inhalers for asthma Chronic obstructive pulmonary disease in over 16s: diagnosis and management Cystic fibrosis: diagnosis and management Asthma: diagnosis, monitoring and chronic asthma management Bronchiolitis in children: diagnosis and management Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma NHS England Specialised Commissioning: National programmes of care and clinical reference groups NHS England Specialised Commissioning: Key documents Links to key documents, national programmes of care, and clinical reference groups are found below. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.ĭrugs carrying the NHS England logo are commissioned by them. Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol ) which may be off-label, unless otherwise stated. Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary. NHS Cheshire and Merseyside Commissioning Policies Respiratory system Until such time as a single suite of commissioning policies can be developed and adopted, NHS Cheshire and Merseyside will continue to adopt and operate the CCG policies it has inherited at Place/borough level, which means that there will be no immediate change in commissioning policy for local people resident in those Places/boroughs from what was in place prior to 1st July 2022. ![]() On 1st July 2022 NHS Cheshire and Merseyside Integrated Care Board (ICB) became the new statutory body responsible for ensuring health care services are available to meet the reasonable needs of the people of Cheshire & Merseyside.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |